Triple negative breast cancer

Common Name(s)

Triple negative breast cancer

Triple negative breast cancer (TNBC) describes any type of breast cancer that lacks three types of receptors that are often used for targeted treatments. These three types of receptors are estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2/neu). These receptors are involved in cell signaling and are found on affected cells in breast cancer that is not TNBC. There are different forms of TNBC, and about 10-20 percent of women who are diagnosed with breast cancer have a TNBC form.

Women who are younger in age, African American or Hispanic, and/or have mutations in the BRCA1 gene are more likely to have TNBC. TNBC often spreads more quickly than other types of breast cancer and presents a higher risk of coming back or recurring, especially in the first few years after treatment. After the first 3-5 years following treatment, the risk of recurrence of TNBC matches that of non-TNBC.

TNBC is diagnosed by taking a biopsy, or tissue sample, of the cancer. TNBC is less likely to respond to hormonal treatments but often does respond well to chemotherapy, radiation therapy, and surgery. If you have been diagnosed with TNBC, talk to your doctor about the most current treatment options. In addition, a genetic counselor can help discuss inheritance and risks to other family members. Support groups are a good source of information and can connect you with others who have been affected by breast cancer.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Triple negative breast cancer" for support, advocacy or research.

Logo
Bay Area Cancer Connections

We support people touched by breast and ovarian cancer by providing comprehensive, personalized services in an atmosphere of warmth and compassion.

http://www.bcconnections.org

Last Updated: 21 May 2015

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Triple negative breast cancer" returned 995 free, full-text research articles on human participants. First 3 results:

Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells.
 

Author(s): Chun-Yu Liu, Ka-Yi Lau, Chia-Chi Hsu, Ji-Lin Chen, Chia-Han Lee, Tzu-Ting Huang, Yi-Ting Chen, Chun-Teng Huang, Po-Han Lin, Ling-Ming Tseng

Journal:

 

Triple negative breast cancer (TNBC) lacks specific drug targets and remains challenging. Palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor is approved for metastatic estrogen receptor (ER)-positive and human epithermal growth factor 2 (HER2)-negative breast cancer. ...

Last Updated: 31 Dec 1969

Go To URL
Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.
 

Author(s): Qiuhong Tian, Peng Du, Sen Li, Zhenzhu Bai, Yong Yang, Jinsheng Zeng

Journal: Medicine (Baltimore). 2017 Nov;96(45):e8389.

 

Triple-negative breast cancer (TNBC) lacks the expression of the estrogen receptor, progesterone receptor, and receptor tyrosine-protein kinase erbB-2 (HER2/neu), which renders hormone-related endocrine and targeted therapy essentially futile.

Last Updated: 31 Dec 1969

Go To URL
Treatment of triple-negative breast cancer with Chinese herbal medicine: A prospective cohort study protocol.
 

Author(s): Hui Meng, Nan Peng, Mingwei Yu, Xu Sun, Yunfei Ma, Guowang Yang, Xiaomin Wang

Journal: Medicine (Baltimore). 2017 Nov;96(44):e8408.

 

Triple-negative breast cancer (TNBC) is featured with the biological properties of strong aggressive behaviors, rapid disease progression, high risk of recurrence and metastasis, and low disease free survival. Patients with this tumor are insensitive to the endocrine therapy and target ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Triple negative breast cancer" returned 69 free, full-text review articles on human participants. First 3 results:

MicroRNAs in the prognosis of triple-negative breast cancer: A systematic review and meta-analysis.
 

Author(s): Lingshuang Lü, Xuhua Mao, Peiyi Shi, Biyu He, Kun Xu, Simin Zhang, Jianming Wang

Journal: Medicine (Baltimore). 2017 Jun;96(22):e7085.

 

Triple-negative breast cancer (TNBC) is a heterogeneous group of tumors characterized by their aggressive nature and poor associated survival. MicroRNAs (miRs) have been found to play an important role in the occurrence and development of human cancers, but their role in the prognosis ...

Last Updated: 31 Dec 1969

Go To URL
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.
 

Author(s): Alberto Ocana, Atanasio Pandiella

Journal: Oncotarget. 2017 Mar;8(13):22218-22234.

 

Triple negative breast cancer (TNBC) is still an incurable disease despite the great scientific effort performed during the last years. The huge heterogeneity of this disease has motivated the evaluation of a great number of therapies against different molecular alterations. In this ...

Last Updated: 31 Dec 1969

Go To URL
Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.
 

Author(s): Sayem Miah, Charles A S Banks, Mark K Adams, Laurence Florens, Kiven E Lukong, Michael P Washburn

Journal: Mol Biosyst. 2016 Dec;13(1):42-55.

 

Understanding the complexity of cancer biology requires extensive information about the cancer proteome over the course of the disease. The recent advances in mass spectrometry-based proteomics technologies have led to the accumulation of an incredible amount of such proteomic information. ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 14 Jan 2018

Go to URL
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
 

Status: Recruiting

Condition Summary: Triple Negative Breast Cancer

 

Last Updated: 3 Jan 2018

Go to URL
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
 

Status: Not yet recruiting

Condition Summary: Triple-Negative Breast Cancer

 

Last Updated: 9 Dec 2017

Go to URL